Protalix BioTherapeutics, Inc. (PLX)

1,2500 +0,1100 (+9,65%) Börsenschluss: 04:00PM EDT

Protalix BioTherapeutics, Inc.

Science Park
2 Snunit St. POB 455
Karmiel 2161401
Israel
972 4 902 8100
https://www.protalix.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 208

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Dror Bashan	President, CEO & Director	1,38M	N/A	1967
Mr. Eyal Rubin M.B.A.	Senior VP, CFO, Treasurer & Corporate Secretary	686,78k	N/A	1976
Mr. Yaron Naos	Senior Vice President of Operations	513,82k	N/A	1964
Ms. Yael Fellous	Vice President of Human Resources	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Corporate Governance

Protalix BioTherapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 4, Vorstand: 8, Shareholderrechte: 1, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.